重症SARS-CoV-2患者接受静脉-静脉体外膜氧合时早期急性肾损伤及转为肾脏替代治疗的情况
该回顾性分析在德国汉堡-埃彭多夫大学医学中心开展,纳入2020年3月1日至2021年7月31日期间91例因SARS-CoV-2需要vv-ECMO的重症患者。结果显示45%发生早期急性肾损伤,38%发生晚期急性肾损伤,16%未发生急性肾损伤;70%的患者在ICU期间需要肾脏替代治疗,早期急性肾损伤组中93%需要,晚期急性肾损伤组中74%需要。早期急性肾损伤的危险因素包括较年轻年龄(OR 0.94)和较高的SAPS II评分(OR 1.12)。接受与未接受肾脏替代治疗的患者基线特征相当,但接受肾脏替代治疗者入院时SAPS II和SOFA评分更高,ICU死亡率分别为69%和56%(p=0.23),无显著差异。
要点
- 91例接受vv-ECMO的重症COVID-19患者中,45%(n=41)发生早期急性肾损伤,38%(n=35)发生晚期急性肾损伤,16%(n=15)未发生急性肾损伤。
- 70%(n=64)的患者在ICU期间需要肾脏替代治疗,其中早期急性肾损伤组93%需要,晚期急性肾损伤组74%需要。
- 早期急性肾损伤的危险因素为较年轻年龄(OR 0.94,95%CI 0.90-0.99,p=0.02)和较高的SAPS II评分(OR 1.12,95%CI 1.06-1.19,p<0.001)。
- 接受肾脏替代治疗的患者入院时SAPS II(41 vs 37分,p<0.05)和SOFA评分(13 vs 12分,p<0.05)显著更高,但ICU死亡率与未接受肾脏替代治疗者无显著差异(69% vs 56%,p=0.23)。
- 接受肾脏替代治疗的患者ICU停留时间中位数更长(36 vs 28天,p=0.27),但差异未达统计学显著。
适用人群与场景
- 2020年3月1日至2021年7月31日在德国汉堡-埃彭多夫大学医学中心ICU接受治疗的91例重症SARS-CoV-2需要vv-ECMO的患者。
研究设计与关键结果
- 研究类型为回顾性分析,单中心,纳入91例重症SARS-CoV-2需要vv-ECMO的患者;中位年龄57岁(IQR 49-64),67%(n=61)为男性;入院时中位SAPS II评分40分(34-46),SOFA评分12分(10-14)。
- 急性肾损伤分期:早期急性肾损伤45%(n=41),晚期急性肾损伤38%(n=35),无急性肾损伤16%(n=15)。
- 肾脏替代治疗需求:总70%(n=64),早期急性肾损伤组93%,晚期急性肾损伤组74%。
- 早期急性肾损伤危险因素:年龄较小(OR 0.94,95%CI 0.90-0.99,p=0.02)和SAPS II评分较高(OR 1.12,95%CI 1.06-1.19,p<0.001)。
- 接受与未接受肾脏替代治疗的患者基线特征相当;接受肾脏替代治疗者入院时SAPS II(41 vs 37分,p<0.05)和SOFA评分(13 vs 12分,p<0.05)显著更高。
- ICU停留时间中位数:接受肾脏替代治疗组36天 vs 未接受组28天(p=0.27)。
- ICU死亡率:接受肾脏替代治疗组69%(n=44) vs 未接受组56%(n=27),p=0.23。
证据类型、等级与局限
- 证据类型:回顾性分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于接受vv-ECMO的重症COVID-19患者,应警惕早期急性肾损伤的高风险(45%),并注意肾脏替代治疗需求高(70%)。
- 早期急性肾损伤与较年轻年龄和较高的SAPS II评分相关,提示病情严重程度是重要风险因素。
- 接受肾脏替代治疗的患者死亡率与未接受者无显著差异,但肾脏替代治疗组病情更重、ICU停留时间更长。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Critically ill patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) requiring veno-venous extracorporeal membrane oxygenation (vv-ECMO) are at risk for acute kidney injury (AKI). Currently, the incidence of AKI and progression to kidney replacement therapy (RRT) in critically ill patients with vv-ECMO for severe COVID-19 and implications on outcome are still unclear.
METHODS: Retrospective analysis at the University Medical Center Hamburg-Eppendorf (Germany) between March 1st, 2020 and July 31st, 2021. Demographics, clinical parameters, AKI, type of organ support, length of ICU stay, mortality and severity scores were assessed.
RESULTS: Ninety-one critically ill patients with SARS-CoV-2 requiring ECMO were included. The median age of the study population was 57 (IQR 49-64) years and 67% (n = 61) were male. The median SAPS II and SOFA Score on admission were 40 (34-46) and 12 (10-14) points, respectively. We observed that 45% (n = 41) developed early-AKI, 38% (n = 35) late-AKI and 16% (n = 15) no AKI during the ICU stay. Overall, 70% (n = 64) of patients required RRT during the ICU stay, 93% with early-AKI and 74% with late-AKI. Risk factors for early-AKI were younger age (OR 0.94, 95% CI 0.90-0.99, p = 0.02) and SAPS II (OR 1.12, 95% CI 1.06-1.19, p < 0.001). Patients with and without RRT were comparable regarding baseline characteristics. SAPS II (41 vs. 37 points, p < 0.05) and SOFA score (13 vs. 12 points, p < 0.05) on admission were significantly higher in patients receiving RRT. The median duration of ICU (36 vs. 28 days, p = 0.27) stay was longer in patients with RRT. An ICU mortality rate in patients with RRT in 69% (n = 44) and in patients without RRT of 56% (n = 27) was observed (p = 0.23).
CONCLUSION: Critically ill patients with severe SARS-CoV-2 related ARDS requiring vv-ECMO are at high risk of early acute kidney injury. Early-AKI is associated with age and severity of illness, and presents with high need for RRT. Mortality in patients with RRT was comparable to patients without RRT.
参考来源
- Roedl K, De Rosa S, Fischer M, et al. Early acute kidney injury and transition to renal replacement therapy in critically ill patients with SARS-CoV-2 requiring veno-venous extracorporeal membrane oxygenation. Ann Intensive Care. 2023. PMID: 37999776. doi:10.1186/s13613-023-01205-x
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。